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Abstract
Background
In Vietnam, a rapid decline of P. falciparum malaria cases has been documented in the past
years, the number of Plasmodium falciparum malaria cases has rapidly decreased passing
from 19.638 in 2012 to 4.073 cases in 2016. Concomitantly, the spread of artemisinin resis-
tance markers is raising concern on the future efficacy of the ACTs. An evaluation of the clin-
ical impact of the artemisinin resistance markers is therefore of interest.
Methods
The clinical effectiveness of dihydroartemisinin-piperaquine therapy (DHA-PPQ) has been
evaluated in three districts characterized by different rates of ART resistance markers: K13
(C580Y) mutation and delayed parasite clearance on day 3 (DPC3). Patients were stratified
in 3 groups a) no markers, b) one marker (suspected resistance), c) co-presence of both
markers (confirmed resistance). In the studied areas, the clinical effectiveness of DHA-PPQ
has been estimated as malaria recrudescence within 60 days.
Results
The rate of K13(C580Y) ranged from 75.8% in Krong Pa to 1.2% in Huong Hoa district.
DPC3 prevalence was higher in Krong Pa than in Huong Hoa (86.2% vs 39.3%). In the two
districts, the prevalence of confirmed resistance was found in 69.0% and 1.2% of patients,
respectively. In Thuan Bac district, we found intermediate prevalence of confirmed resis-
tance. Treatment failure was not evidenced in any district. PPQ resistance was not evi-
denced. Confirmed resistance was associated to the persistence of parasites on day 28 and
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to 3.4-fold higher parasite density at diagnosis. The effectiveness of malaria control strate-
gies was very high in the studied districts.
Conclusion
No treatment failure has been observed in presence of high prevalence of ART resistance
and in absence of PPQ resistance. K13(C580Y) was strongly associated to higher parasite-
mia at admission, on days 3 and 28. Slower parasite clearance was also observed in youn-
ger patients.
Introduction
Artemisinin (ART) resistance was first described in Cambodia [1–4] and, successively, in dif-
ferent areas of the Greater Mekong sub-region (GMS) [5–9] including Vietnam[10,11]. ART
resistance is defined as delayed parasite clearance (DPC) following artemisinin-based combi-
nation therapy (ACT) resulting in a prolonged parasite clearance time [12,13].
A molecular marker of ART resistance (mutations on P. falciparum K13 propeller gene)
was found to be associated with DPC [8,11,14]. Some K13 mutations and DPC on day 3
(DPC3) are markers that are currently used to identify ART resistance, the co-presence of the
two markers, is defined as “confirmed endemic artemisinin resistance” [12].
Anyway, the definition and the clinical impact of ART resistance are still controversial [15].
As a matter of facts, WHO updates from 2011 to 2018 reveal that the definition of ART resis-
tance is undergoing a constant evolution. The majority of reports on artemisinin resistance
did not take in consideration its effects on clinical treatment failure [8,11,16–20]. A minority
of reports displayed that the presence of both ART resistance markers was associated to clinical
failure [21–23] while others reports did not confirm this observation [24,25]. On the other
hand, the co-occurrence of ART resistance and resistance to the partner drugs was described
to be associated to high rates of clinical treatment failure [23,26]. In addition, the available
ART resistance markers are affected by some technical limitations: i) their sensitivity and spec-
ificity are still undefined [27]; ii) resistance to mefloquine and piperaquine is, by itself, a dem-
onstrated cause of clinical treatment failure of ACTs but the absence of a genetic marker
cannot exclude drug resistance; iii) the rate of clearance of parasitized erythrocytes is multi-
factorial being influenced by resistance to anti-malarial drugs and host factors, such as immu-
nity and mutations affecting erythrocyte viability (G6PD deficiency and thalassemias) that
may vary in the different areas.
In Vietnam high prevalence of the available ART resistance markers has been observed in
some provinces [28,29] but the evidence of clinical treatment failure has been reported in one
district with demonstrated resistance to piperaquine [23]. Although the national program for
the eradication of malaria has provided very promising results, the increasing frequency of
ART resistance markers [28] has raised concerns due to many previous episodes of resurgence
that have been already observed worldwide following phases of apparent malaria control.
The objective of the present study is to evaluate the impact of different rates of ART resis-
tance markers found in three Vietnamese districts on the efficacy of the current anti-malarial
therapy. As standard index to assess ACT efficacy we utilized malaria recrudescence within 60
days from ACT treatment.
We also evaluated the interference of some known confounding factors such as mutations
affecting erythrocytes and piperaquine resistance. The effectiveness of malaria control
Artemisinin resistance markers in Vietnam
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strategies has been estimated in the different areas (rate of decay of malaria prevalence and
prevalence of asymptomatic carriers) to exclude a possible interference.
Materials and methods
Ethical clearance
The study was conducted in accordance with Good Clinical Practice guidelines and the Decla-
ration of Helsinki and was approved by the Hue University of Medicine and Pharmacy Ethical
Board. Written informed consent was obtained from the participants or from the legal repre-
sentative of children aged less than 18 years before entering the study.
Study sites, participants and sample collection (Clinical procedures)
This study was conducted from 2012 to 2016 in three areas of Vietnam: (i) the Huong Hoa dis-
trict of Quang Tri province located in the North Central Coast region at the Laotian border;
(ii) the Krong Pa district of Gia Lai province located in the Central Highlands) at the Cambo-
dian border; and (iii) the Thuan Bac district of Ninh Thuan province located in the South Cen-
tral Coast. In Huong Hoa, blood samples were collected from 84 malaria patients in 2014. In
Krong Pa and Thuan Bac, blood samples were collected from 29 and 20 malaria patients,
respectively, in 2015. Table 1 shows the major characteristics of the subjects enrolled in this
study.
Patients with uncomplicated P. falciparum malaria were enrolled during the season of high
malaria transmission from August to November (2014–2015). The inclusion criteria used dur-
ing the study were: a) non-complicated malaria patients, b) age: between 3 and 60 years; Para-
site counting has been performed in the laboratory of the local dispensary, where patients have
been admitted, according to standard procedures. For qPCR analysis 200–300μl of capillary
blood were sampled using a finger prick lancet (Accu-Chek, Roche) and collected in an EDTA
microtube (Microvette CB300, Sarstedt) and immediately stored at -20˚C. Patients were
screened and treated on-site daily with standard dihydroartemisinin-piperaquine therapy
(Artekin, DP tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine phos-
phate) for three days following the National Malaria Treatment Guidelines [30]. All doses
were administered and recorded under the supervision of a qualified member of staff
Table 1. Characteristics of subject registered in the studied areas.
Characteristics Huong Hoa Krong Pa Thuan Bac
General population Malaria patients General population Malaria patients Malaria patients
Number of samples 763 84 200 29 20
Female 41% 38% 57% 17.2% 60%
Male 59% 62% 43% 82.8% 40%
Ethnicity (%) Vaˆn Kie`ˆu
(93.4%)
Pa Coˆ
(4.8%)
Kihn
(1.8%)
Vaˆn Kie`ˆu
(100%)
Jarai
(97%)
Xa Deng
(3%)
Jarai
(100%)
Ra Glai
(100%)
Age range N (%)
�5 yr 63 (8.2%) 4 (4.8%) 8 (4.0%) 0 (0.0%) 0 (0.0%)
6–10 yr 110 (14.4%) 14 (16.7%) 27 (13.5%) 1 (3.4%) 2 (10.0%)
11–15 yr 112 (14.7%) 20 (23.8%) 27 (13.5%) 2 (6.9%) 0 (0.0%)
16–20 yr 84 (11.0%) 13 (15.5%) 12 (6.0%) 3 (10.3%) 2 (10.0%)
>20 yr 394 (51.6%) 33 (39.3%) 126 (63%) 23 (79.3%) 16 (80.0%)
https://doi.org/10.1371/journal.pone.0214667.t001
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designated by the principal investigator. Patients were supervised and their health conditions
were evaluated by continued careful observation. They were screened before the drug treat-
ment on day 0 and after the drug treatment on days 3 and 28 using microscopy and quantita-
tive real-time polymerase chain reaction (qPCR) to evaluate parasitaemia. Drugs were
administered to the patients at the local dispensary and patients were asked to return to the
dispensary in case of recrudescence. Clinical and laboratory testing were also conducted dur-
ing the follow-up. To evaluate the rate of asymptomatic carriers in the studied districts during
the season of low malaria transmission, blood sampling was conducted from the general popu-
lation living in the same villages as those of enrolled patients. In Krong Pa, 200 subjects were
screened from June to July 2015, while in Huong Hoa, a total of 763 subjects were screened
(663 in December 2013 and 100 in December 2015). Malaria recrudescence was retrospectively
assessed in malaria patients admitted in the three districts from 2014 to 2016. All patients com-
plied with the follow up study as they were resident in the villages close to the local dispensary.
National data on malaria collection
The annual data of incidence and prevalence of malaria were collected from:
i. The General Statistic Yearbook (Viet Nam) of the years from 2012 to 2016;
ii. The Annual Reports of the Institute for Malariology, Parasitology and Entomology (Viet
Nam) from 2012 to 2016.
iii. World Health Organization (WHO). National Malaria Programme Review–Viet Nam.
2018
Laboratory procedures
Microscopic analysis of blood smears. Thick blood smears were examined on days 0, 3,
and 28 and stained with 10% Giemsa. Parasitaemia was estimated by counting the number of
asexual parasites in 500 leucocytes (white blood cells, WBCs), and parasite density (parasites/
μL of blood) was then calculated following the guidelines of the WHO, assuming a WBC count
of 8,000. Blood smears with discordant results (differences in assessment of species, parasite
density >50%, or the presence of parasites) were re-examined by a third independent micros-
copist, and parasite densities were calculated by averaging the two closest counts [31].
P. falciparum DNA extraction and quantification by qPCR. qPCR was performed on
days 0, 3, and 28 on all samples. DNA was extracted from 100 μL of whole blood preserved at
-20˚C using the salting-out method according to standard procedures [32]. Briefly, red blood
cells were lysed with Red Cells Lysis Buffer solution (10 mM Tris-HCl, 5 mM MgCl2, and 10
mM NaCl, pH 7.6). Then, the cell pellet was incubated at 55˚C for 20 min with White Cells
Lysis Buffer solution (Tris-HCl 10 mM, 10 mM ethylenediaminetetraacetic acid, and 50 mM
NaCl, pH 7.6) in the presence of 10% sodium dodecyl sulphate and 20 mg/mL proteinase K
solution. DNA purification and precipitation were consecutively performed using a saturated
salt solution (6M NaCl) and isopropanol, respectively. After washing with 70% ethanol, the
DNA pellet was re-suspended in sterile H2O. DNA amplification was performed using primers
and probes for the 18S rRNA gene of P. falciparum as previously described with minor modifi-
cations [33] DNA was amplified with 1× final reaction buffer, 1.5 mM MgCl2, 0.2 mM deoxy-
nucleotide triphosphates (dNTPs), each primer at 300 nM, 100 nM TaqMan probe, and 1 U of
Platinum Taq polymerase (Life Technologies, CA, USA).
Amplification and detection were performed using the CFX96 Touch Real-Time PCR
Detection System (Biorad) and programmed as follows: 95˚C for 3 min, followed by 45 cycles
Artemisinin resistance markers in Vietnam
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at 95˚C for 15 s and 60˚C for 45 s. Parasite density (parasites/μL) was estimated using a stan-
dard curve obtained from 10-fold serial dilutions of P. falciparum DNA in culture with known
parasitaemia (from 100,000 to 10 parasites/μL), using CFX Manager Software 3.1 (Biorad).
Mutations in the K13 propeller domain gene. The P. falciparum K13 propeller domain
gene was amplified by nested PCR as previously described [14]. Amplified products of PCR
were purified using Exo I & Fast AP (Carlo Erba), and sequencing was performed by Macro-
gen (Netherland). Electropherograms were visualised and analyzed with ApoE software and
alignments were performed by Muscle 3.8 software with the K13 sequence of the 3D7 clone
(PF3D7_1343700) as the reference.
P. falciparum plasmepsin 2 (PfPM2) copy number determination. The copy number of
the PfPM2 gene was determined by qPCR as previously described [34], using β-tubulin as an
internal standard. The PfPM2 copy number was calculated by the 2-ΔCt method.
Molecular diagnosis of red cell mutations. Haemoglobin E (Hb E), haemoglobin con-
stant spring (Hb CS), and glucose-6-phosphate-dehydrogenase (G6PD) deficiency variant
Viangchan (G6PD D.) as one of the most common variants throughout South-east Asian pop-
ulations [35,36] were detected by qPCR using a Taqman probe specific for the wild-type (WT)
sequence and one specific for each mutant (MUT) sequence. Primers (forward and reverse)
and Taqman fluorescence-labelled probes (WT and MUT) for qPCR were designed using Bea-
con Designer.
Hb E detection (Ref. Seq: NG_000007.3) was performed using a mixture of 1 mM dNTPs, 3
mM MgCl2, each primer at 400 nM (forward: 5
0-CCTGAGGAGAAGTCT-30 and reverse:
50-TGTCTTGTAACCTTGAT-30), 125 nM WT probe (50-[FAM]AGGGCCTCACCAC
[BHQ1]-30), 150 nM MUT probe (50-[HEX]AGGGCCTTACC[BHQ1]-30), and 1 U of
Platinum Taq DNA (Invitrogen). Amplification was performed under the following condi-
tions: 95˚C for 3 min, then 45 cycles at 95˚C for 15 s, 60˚C for 20 s, and 72˚C for 20 s.
G6PD D. detection (Ref. Seq: NG_009015.1) was performed using 1 mM dNTPs, 4 mM
MgCl2, each primer at 400 nM (forward: 5
0-CCAGGACCACATTGTTG-30 and reverse: 50-AC
CCAAGGAGCCCATTCT-30),175 nM WT probe (50-[HEX]ATTTCAACACCTTGACCTGA
[BHQ1]-30), 275 nM MUT probe (50-[Cy5]ATTTCAACATCTTGACCTGA[BHQ2]-30),
and 1 U of Platinum Taq DNA (Invitrogen). Amplification was performed under the following
conditions: 95˚C for 3 min, then 45 cycles at 95˚C for 15 s, 57˚C for 20 s, and 72˚C for 20 s.
Hb CS detection (Ref. Seq: NG_000006.1) was performed using 10 μL of 2× Taqman
(Applied Biosystem) universal master mix, each primer at 400 nM (forward: 50-GACAAGTT
CCTGGCTTCT -30 and reverse: 50-ATAGAGAGAACCCAGGCA -30), 300 nM WT probe (50-
[FAM]GGCTCCAGCTTAACGGTATTTGG[BHQ1]- 30), and 100 nM MUT probe (50-[Tx
Red]GGCTCCAGCTTGACGGTATTTGG[BHQ1]- 30) (Invitrogen). Amplification was per-
formed under the following conditions: 50˚C for 2 min, 95˚C for 10 min, then 45 cycles at
95˚C for 15 s, 57˚C for 30 s, and 60˚C for 30 s. For each protocol, detection and analysis were
performed using CFX96 Touch Real-Time PCR Detection System.
Statistical analysis. Comparison between categorical variables was performed using a
Pearson’s chi-square or Fisher exact test, where appropriate (STATA software version 13).
Comparison between quantitative variables was performed using Student’s t-test (Graph Pad
Prism 7.3). A two-tailed p-value of less than 0.05 was considered statistically significant.
Results
Variation of malaria cases in three Vietnamese districts
Fig 1A shows the percentage variation in the number of P. falciparum malaria cases from 2012
to 2016 in the three studied districts. Those data are in agreement with the national data (Fig
Artemisinin resistance markers in Vietnam
PLOS ONE | https://doi.org/10.1371/journal.pone.0214667 April 2, 2019 5 / 12
1B). In Krong Pa and Huong Hoa, the number of malaria cases decreased by more than 95%
from 2012 to 2016. In Thuan Bac an abrupt decrease in the number of malaria cases (87.5%)
was also observed in the last 2 years which followed an increase in the number of cases from
2012 to 2014. The reason for this biphasic behavior may be influenced by the large number of,
immunologically naive, workers that moved in the area from 2012 to 2014.Those data indicate
that, in the studied areas, the decline of malaria cases reflects the national data and that control
strategies were similarly efficient.
Prevalence of ART resistance markers in three Vietnamese districts
To verify the clinical impact of the two ART resistance markers, K13 gene mutations and
DPC3, we determined their prevalence in three separated districts (Huong Hoa, Krong Pa,
Thuan Bac). To exclude the interference that may be exerted by piperaquine resistance, we
measured the presence of a specific and sensitive marker of piperaquine resistance (multico-
pies of PfPM2 gene). In the three districts, DPC3 and K13 mutation rates were measured in a
group of P.falciparum malaria patients. Parasitemia was measured at admission and then on
days 3 and 28 by microscopy and qPCR. As expected, microscopy revealed lower sensitivity
and accuracy at low parassitemia [37]. The qPCR method was carefully calibrated displaying a
limit of detection (LOD) of 1–10 parasites/μl with a coefficient of variation among replicates
lower than 30% measured at 100 parasites/μl. qPCR was performed using highly purified DNA
extracted from -20˚C preserved blood samples rather than blood dried on filter paper because
of better sensitivity and reproducibility. It should be noticed that measuring parasitemia by
microscopy the rate of DPC3 was approximately 25% lower than by qPCR (Table 2). The
mutations on the P.falciparum K13 gene were assessed by DNA sequencing. In accordance
with previous reports we distinctively detected the C580Y mutation, the most common muta-
tion on K13 gene found in Vietnam [28].
Table 2 shows the largely different rates of ART resistance markers measured in the three
districts by microscopy and qPCR. The mean parasitemia levels at admission and on day 3
were higher in Krong Pa than in the other two districts. By qPCR on day 28, we observed the
presence of circulating parasites only in Krong Pa and in Thuan Bac. At microscopic
Fig 1. Percentage of variation in P.falciparum malaria cases in Huong Hoa, Krong Pa and Thuan Bac districts, from 2012 to
2016 (A). Number of malaria cases and deaths in Vietnam from 2012 to 2017 (B).
https://doi.org/10.1371/journal.pone.0214667.g001
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examination we could not evidence the presence of gametocytes but due to extremely low par-
asite density observed by qPCR we cannot exclude their eventual presence. Table 2 shows
nearly absence of piperaquine resistance in all studied districts. Resistance has been searched
using a sensitive and specific molecular marker (multi-copies of PfPM2 gene) (S1 Fig); (S1
Row Data).
Evaluation of the impact of ART resistance on treatment effectiveness. According to a
WHO classification [12] we divided the patients in 3 groups: A) no ART resistance (absence of
both AR resistance markers), B) suspected endemic resistance (presence of only one marker),
C) confirmed endemic resistance to ART (presence of both markers) (Table 3). Independently
to the different degrees of confirmed ART resistance, in the three districts we did not evidence
signs of clinical treatment failure both in the enrolled patients and in the three districts evaluat-
ing the official medical records for recrudescence within 60 days after treatment (from 2014 to
2016) (Table 2). Although unlikely, as many patients live in a village close to a medical dispen-
sary where antimalarial drugs are administered, self-medication cannot be totally excluded.
Table 3 also shows that group C displays much higher parasitemia at admission than groups A
and B accompanied by higher rates of patients with circulating parasites on day 28.
Table 2. Clinical and parasitological parameters (measured by microscopy and qPCR) in Huong Hoa, Krong Pa and Thuan Bac districts.
Parameters Huong Hoa (n = 84) Krong Pa
(n = 29)
Thuan Bac
(n = 20)
Frequency of positivity on day 3 measured by microscopy and qPCR 27.2%
39.3%(
�)
68.1%
86.2%(1,�)
32.5%
40.0%(�)
Frequency of positivity on day 28 measured by microscopy and qPCR 0.0%
0.0%(
�)
8.0%
17.2%(2,�)
12.6%
20.0%(2,�)
Frequency of K13 (C580Y) 1.2% 75.8%(1) 15.0%
Frequency of PfPM2 multi-copies 1.2% 0.0% 0.0%
Mean parasitemia (parasites/μl) on day 0 by microscopy and qPCR 25423
33839(�)
59223
73801(�)
33665
45997(�)
Mean parasitemia (parasites/μl) in positive patients on day 3 by qPCR 100 165 81
Mean parasitemia (parasites/μl) in positive patients on day 28 by qPCR — 18 14
Frequency of malaria recrudescence on day 60 0.0% 0.0% 0.0%
Percent decrease of the number of malaria cases in the last years 95.0%
(from 2012)
97.0%
(from 2012)
87.0%
(from 2014)
Frequency of asymptomatic carriers 1.2% 1.0% —
n: number of studied patients.
(1) The value is significantly different (p < 0.05) in comparison to the two other values belonging to the same category.
(2) The value is significantly different (p < 0.05) in comparison to the lowest value belonging to the same category. The frequency of malaria recrudescence was
retrospectively assessed in malaria patients admitted in the three districts from 2014 to 2016.
(�) Frequency of positivity on days 3 and 28 measured by qPCR.
https://doi.org/10.1371/journal.pone.0214667.t002
Table 3. Clinical and parasitological parameters in the patients grouped according to WHO definition of endemic ART resistance (n: Number of patients).
No
ART Resistance
(B) Suspected endemic
ART Resistance
(C) Confirmed endemic
ART resistance
Parameters n = 63 n = 48 n = 22
Mean parasitemia
(parasites/μl) on day 0
26004 47703 89759
Mean parasitemia (parasites/μl) in positive patients on day 3 0 95 176
Mean parasitemia(parasites/μl) in positive patients on day 28 0 14 18
Frequency of DPC on day 28 0% 8.3% 22.7%
https://doi.org/10.1371/journal.pone.0214667.t003
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Effect of potential confounding factors on the assessment of DPC3
We analyzed the interference of some potential confounding factors on the rate of clearance of
parasites. The prevalence of some common human mutations selected by malaria such as
G6PD deficiency variant Viangchan, Haemoglobin E and Haemoglobin Constant Spring were
measured in the general population and in malaria patients. Table 4 shows that the prevalence
of the studied mutations was not significantly different in the general population and in
malaria patients which displayed DPC3. This observation indicates that those mutations do
not apparently affect the parasite clearance rate (p> 0.05). It should be, anyway noticed that a
larger cohort of patients should be studied to increase the statistical power of the results. The
mean age of the patients displaying DPC3 was similar to the age of patients without DPC3
(23.7 vs 25.9; p> 0.05). On the contrary, a subset of patients characterized by a slower clear-
ance of parasites on day 3 (more than 5% of infected parasites still present on day 3) showed a
significantly lower (p< 0.05) mean age (14.0 years) than patients presenting faster parasite
clearance (24.7 years). The gender of patients did not play a role on DPC3. In conclusion we
could not identify any factor that may clearly affect the different distribution of ART resistance
markers observed in the studied districts. In addition, also the effectiveness of malaria control
measures such as: bed nets, vector control, and quality of health system, appear homogeneous
in the three districts limiting their possible interference.
Discussion
In the past years a sustained decline in the number of P. falciparum malaria cases has been
observed in Vietnam. On the other hand, the increasing rates of ART resistance markers, the
appearance of piperaquine resistance at the Cambodian border [23,38], the threat of multidrug
resistant parasites and a moderate increase of malaria cases observed in 2017 in Vietnam, are
raising concern. On the other hand, the actual relevance of the ART resistance markers in pre-
dicting the risk of treatment failure is still debated [15], the significance of artemisinin resis-
tance is constantly updated [12,39–46] and the available literature is sometime incomplete or
contradictory[8,11,16,20–25]. To establish the impact of ART resistance on clinical treatment
failure we followed a comprehensive, in dept, approach: we measured the rates of suspected
endemic artemisinin resistance and confirmed endemic artemisinin resistance according to
the current WHO guidelines[12,45] to identify areas with markedly different prevalence of
confirmed ART resistance (from 1.7% to 75.8%). In the studied districts we assessed the preva-
lence of clinical treatment failure (recrudescence within 60 days) in a large number of subjects.
We also tested PPQ resistance by a validated marker in all districts. Some frequent human
mutations known to affect parasite clearance and the efficacy of malaria control strategies were
Table 4. Comparison of frequency (%) of human mutations (G6PD Deficiency, Haemoglobin E, and Haemoglobin Constant Spring) between the general popula-
tion and malaria patients with and without DPC (n = number of patients).
G6PD Deficiency
variant Viangchan
(%)
Haemoglobin E
(%)
Haemoglobin
Constant spring
(%)
General population
(n = 400)
9.5 51.5 28.7
Malaria patients
with DPC3
(n = 66)
10.6 45.4 28.7
Malaria patients
without DPC3
(n = 67)
7.5 59.7 34.3
https://doi.org/10.1371/journal.pone.0214667.t004
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evaluated in order to exclude some major confounding factors. In the present report parasite-
mia was measured by microscopy to allow easier comparison with previous reports and by
qPCR to allow the quantification of parasites on days 3 and 28. In addition, qPCR revealed
that K13 (C580Y) variant is associated to much higher parasitemia at admission. In all studied
districts we could not evidence clinical treatment failure (no cases of clinical recrudescence
within two months from the treatment). Our data tend to exclude interferences caused by
human mutations affecting erythrocyte functions or differences of malaria control effective-
ness in the studied districts.
In the two districts displaying the highest and the lowest prevalence of the K13 mutation,
we observed markedly different rates of DPC3 (86.2% vs 39.3%) confirming the association
between the two markers [8,11,20,24]. In patients with parasites mutated at K13 (C580Y), per-
sistence of parasites on day 28 was observed. Interestingly, by quantitative parasite measure-
ment we evidenced that K13 (C580Y) mutation is strongly associated to higher parasite
density at admission, on day 3 and to the presence of residual parasites on day 28 (S1 Fig). The
lack of clinical treatment failure in presence of DPC may be due to the very low parasite den-
sity of residual parasites (from 81 to 165 parasites/ul on day 3 and from 14 to 18 parasites/μl
on day 28). It should be anyway noticed that we cannot exclude that residual parasites were
not gametocytes, moreover we cannot provide evidence on the viability of the parasites at such
low densities It should be also taken in consideration that piperaquine reaches its peak plasma
concentration on day 3–4 and possess a very prolonged half-life (four weeks). Piperaquine
may, therefore, kill the very few and, plausibly, damaged residual parasites observed on days 3
and 28.
The use of quantitative measurements provided additional information: i) the co-occur-
rence of both ART resistance markers was associated to a 3.4 fold higher parasite density at
admission in comparison to patients displaying no ART resistance markers; ii) patients dis-
playing a slower clearance of parasites on day 3 (< 95% of initial density) were significantly
younger than patients displaying faster clearance. Those observations are in accordance with
reports indicating that immunity is a major determinant of the parasite clearance rate [47–49]
that, in turn, is expected to influence parasitemia. As expected, a reduction of malaria immu-
nity has been described [48] in large regions of the GMS, including Vietnam, where malaria
transmission substantially declined in the past 5–10 years. Interestingly, the same report pro-
vides strong evidence that K13 (C580Y) mutation is associated to decreased immunization,
suggesting that lack of acquired immunity may affect the selection on K13 mutations and
cause delayed parasite clearance. It should be also noticed that DPC may promote the spread
of parasites resistant to the partner drug [49] and that resistance to the partner drugs clearly
associated to ACT resistance [50].
In conclusion ART resistance markers are not predictive of clinical failure [24,25]. This
result was not obvious because the available literature is still incomplete or provides conflicting
results[8,11,16,20–25] in addition, the last WHO reports don’t exclude treatment failure in
presence of ART resistance[12,45,46]. Anyway, independently on the causes, more effective
treatments are required to counteract the phenomenon of delayed parasite clearance.
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